Company intelligence / Profile preview

SANGI CO., LTD.

Ownership: Private
Development stage: Commercial

Overview

Sangi pioneered the use of hydroxyapatite, a key component of tooth enamel, in toothpaste. Their APADENT line was the world’s first hydroxyapatite-containing toothpaste, launched in 1980. The company’s proprietary nano-hydroxyapatite is officially approved as an anti-caries agent and is used in a range of remineralizing and restorative oral care products.

Therapeutic areas: OtherInfectious Diseases
Modalities: Hydroxyapatite-based formulations (for dental and oral health)
Industry: Non-Drug Biotech

Drug pipeline

4 assets

acetazolamide

Pre-clinical

Indications: Research model drug

3 more assets in the full pipeline.

Request access →

Partnerships

Collaborates with distributors and possibly academic partners for research

Beyond the preview

Go deeper on SANGI CO., LTD..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SANGI CO., LTD..

Explore the full profile